SABR in high risk prostate cancer: outcomes from two prospective clinical trials with and without elective nodal irradiation

There is limited data on SABR with ENI in high-risk PCa. This study compares two phase II SABR trials with and without ENI in high-risk PCa. Trial1 prescribed 40Gy/5 to prostate and 30G/5 to SVs, while trial2 prescribed 40Gy/5 to prostate and 25Gy/5 to pelvis and SVs. Biochemical control rates were comparable to other RT modalities, and ENI was led to a significant improvement in 4yPSARR without an increase in late toxicity.

https://ift.tt/2FisAdK